12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ramucirumab: Phase III data

Top-line data from the double-blind, international Phase III REGARD trial in 355 patients with metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum or fluoropyrimidine-containing combination therapy showed that 8 mg/kg IV ramucirumab every 2 weeks plus best supportive care (BSC) met the primary endpoint of OS vs. placebo plus BSC. Ramucirumab plus BSC also met the secondary endpoint...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >